摘要
目的探究孟鲁司特钠联合布地奈德雾化吸入治疗慢性阻塞性肺疾病(COPD)的疗效及对患者免疫功能与炎症因子的影响。方法选取2020年12月至2022年12月本院收治的62例COPD患者作为研究对象,按照随机数字表法分为对照组与实验组,每组31例。对照组给予布地奈德雾化吸入治疗,实验组在对照组基础上给予孟鲁司特钠治疗。比较两组临床疗效、治疗前后血清炎症因子[C-反应蛋白(CRP)、白细胞介素6(IL-6)]、免疫功能(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平。结果实验组治疗总有效率为93.55%,高于对照组的74.19%(P<0.05)。治疗前,两组CRP、IL-6水平比较差异无统计学意义;治疗后,实验组CRP、IL-6水平均低于对照组(P<0.05)。治疗前,两组CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)水平比较差异无统计学意义;治疗后,实验组CD4^(+)、CD4^(+)/CD8^(+)水平显著高于对照组,且CD8^(+)明显低于对照组(P<0.05)。结论孟鲁司特钠联合布地奈德雾化吸入治疗COPD效果显著,能有效降低炎症因子水平,改善患者免疫功能。
Objective To explore the efficacy of montelukast sodium combined with budesonide aerosol inhalation in the treatment of chronic obstructive pulmonary disease(COPD)and its influence on immune function and inflammatory factors.Methods 62 patients with COPD in our hospital from December 2020 to December 2022 were selected as the research subjects,and they were divided into control group and experimental group according to the random table number methods,with 31 cases in each group.The control group was treated with budesonide aerosol inhalation,and the experimental group was treated with montelukast sodium on the basis of the control group.The cilinical efficacy,serum inflammatory factors(C-reactive protein[CRP],interleukin 6[IL-6])and immune function(CD4^(+),CD8^(+),CD4^(+)/CD8^(+))levels before and after treatment were compared between the two groups.Results The total effective rate of the experimental group was 93.55%,which was significantly higher than 74.19%of the control group(P<0.05).Before treatment,there was no significant difference in the levels of CRP and IL-6 between the two groups;after treatment,the levels of CRP and IL-6 in the experimental group were lower than those in the control group(P<0.05).Before treatment,there was no significant difference in the levels of CD4^(+),CD8^(+),CD4^(+)/CD8^(+)between the two groups;after treatment,the levels of CD4^(+),CD4^(+)/CD8^(+)in the experimental group were significantly higher than those in the control group,and the levels of CD8^(+)was significantly lower than that in the control group(P<0.05).Conclusion Montelukast sodium combined with budesonide aerosol inhalation in the treatment of COPD has obvious effect,can effectively reduce the level of inflammatory factors,improve the immune function of patients.
作者
邓卫国
吴丹
李桃
DENG Weiguo;WU Dan;LI Tao(Department of Internal Medicine,Fuzhou Municipal Hospital,Fuzhou,Jiangxi,344000,China)
出处
《当代医学》
2022年第31期39-41,共3页
Contemporary Medicine
基金
抚州市指导性科技计划项目(抚科计字[2020]20号,第60项)。
关键词
孟鲁司特钠
布地奈德雾化吸入
慢性阻塞性肺疾病
免疫功能
炎症因子
Montelukast sodium
Budesonide aerosol inhalation
Chronic obstructive pulmonary disease
Immunity
Inflammatory factors